Pharmaceutics | Free Full-Text | Fast-Fed Variability: Insights into Drug Delivery, Molecular Manifestations, and Regulatory Aspects
Practical and Scalable Manufacturing Process for the Key Intermediate of Poly(ADP-Ribose) Polymerase Inhibitor Olaparib | ACS Omega
Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations - ScienceDirect
Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, an
206162Orig1s000
206162Orig1s000
Exploring and comparing adverse events between PARP inhibitors - The Lancet Oncology
Rubraca: Side effects, uses, effectiveness, dosage, and more
Simulated plasma concentration-time profile for (a) single-dose... | Download Scientific Diagram
Olaparib (Lynparza) - Side Effects, Interactions, Uses, Dosage, Warnings | Everyday Health
How to Take LYNPARZA® (olaparib)
Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials - ScienceDirect
How to Take LYNPARZA® (olaparib)
Biomedicines | Free Full-Text | Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance
Lynparza, INN-olaparib
Practical and Scalable Manufacturing Process for the Key Intermediate of Poly(ADP-Ribose) Polymerase Inhibitor Olaparib | ACS Omega
Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors | SpringerLink
Lynparza, INN - olaparib
Lynparza, INN - olaparib
Lynparza, INN - olaparib
Role of PARP Inhibitors in BRCA-Related Malignancies
Lynparza, INN-olaparib
